Skip to Main Content

  • Chronic hypertension:
    • Systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg prior to pregnancy of before 20 weeks of gestation
    • Hypertension that persists beyond the 12th postpartum week
  • Gestational hypertension:
    • New-onset hypertension after midpregnancy without proteinuria that resolves within 12 weeks postpartum
  • Preeclampsia:
    • New-onset hypertension after 20 weeks gestation associated with >300 mg per day proteinuria
    • New-onset seizures in the setting of preeclampsia are defined as eclampsia
  • Preeclampsia superimposed on chronic hypertension

|Download (.pdf)|Print
Hemodynamic Characteristics of Hypertensive Disorders during Pregnancy1
HealthyEarly preeclampsiaLate preeclampsiaGestational or chronic hypertension
Cardiac output6.28.95.09.0
Systemic vascular resistance1,2101,0821,687922
Wedge pressure7.59137
Stroke volume8010458110
LVSWI48613364
Colloid oncotic pressure18171418

1No ranges are given; numbers are presented for comparison as representative values.

|Download (.pdf)|Print
Chronic Hypertension
  • Affects 3% of pregnant population
  • More common in
    • African Americans (up to 44%)
    • Older gravidas (>12% after the age of 35)
Frequently associated with obesity, diabetes mellitus
  • Maternal complications
    • Superimposed preeclampsia
      • 10–25% incidence of progression to preeclampsia
      • 2.7-fold increase in risk for severe preeclampsia
    • Placental abruption
  • Commonly used oral medications1
    • α-Methyldopa
    • Labetalol
      • Metoprolol SR is an alternative
    • Nifedipine SR
  • Less commonly used oral medications1
    • Hydrochlorothiazide
    • Hydralazine (oral)
  • Fetal complications
    • IUGR/low birth rate
    • Fetal demise
  • Contraindicated in pregnancy1
    • ACEIs, ARBs, direct renin inhibitors
    • Propranolol (atenolol)

1Pharmacological options for the treatment of gestational hypertension are the same as those for chronic hypertension.

|Download (.pdf)|Print
Preeclampsia
  • Estimated frequency in healthy nulliparous women is 2–7%
  • Majority of cases (75%): mild, near term or intrapartum onset, negligible increase in risk for adverse outcome
  • Frequency and severity is higher with history of
    • Multiple gestation
    • Chronic hypertension
    • Prior pregnancy with preeclampsia
    • Pregestational diabetes mellitus
    • Thrombophilia
  • Maternal complications
    • Placental abruption (1–4%)
    • Disseminated coagulopathy/HELLP syndrome (10–20%)
    • Pulmonary edema/aspiration (2–5%)
    • Acute renal failure (1–5%)
    • Eclampsia (1%)
    • Liver failure or hemorrhage (1%)
    • Stroke (rare)
    • Death (rare)
    • Long-term cardiovascular morbidity
  • Diagnosis and management is supported by adequate prenatal care
  • Main objective remains the safety of the mother
  • Expectant management for pre-34 weeks remains controversial
  • Multisystem disorder with poorly understood pathomechanism
    • Abnormal vascular response to placentation
    • Placental humoral factors (sFlt-1, sEng) cause endothelial dysfunction in mother
  • Unique to human pregnancy
  • Characterized by
    • Microvascular dysfunction
    • Increased SVR
    • Activation of inflammatory pathways
    • Enhanced coagulation
    • Increased platelet activation and aggregation
    • Endothelial barrier dysfunction
  • Preeclampsia is most likely the common manifestation of a number of diseases affecting pregnant women
  • Fetal effects
    • IUGR/low birth weight
    • Reduced amniotic fluid
    • Restricted placental oxygen exchange, fetal hypoxia and neurological injury
  • Preterm delivery
  • Antihypertensives
    • Little evidence for benefit in mild/moderate cases
    • Severe hypertension (>160 mm Hg systolic, >100 mm Hg diastolic) should be treated to prevent maternal end-organ damage
    • Hydralazine was associated with more maternal side effects ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.